New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

Add-on treatment with apitegromab met the primary endpoint in a Phase III study in patients with waning responses to SOC

BioCentury’s roundup of translational innovations

Revenues from Nurtec ODT sales and Pfizer deal position Biohaven to add SMA asset, anti-convulsive

Muscular dystrophy programs in the clinic cover not only a range of muscle mechanisms but also anti-fibrotic and anti-inflammation ones

Scholar Rock is moving apitegromab (SRK-015) into Phase III this year, but the myostatin blocker is proving to have a more durable effect in some spinal muscular atrophy patient cohorts than others.

Phase II data breathes new life into theory that blocking myostatin can improve muscle growth, function